Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
EB-003 Development Highlights:
Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003 and expected initiation of Phase 1 clinical trial
Reported preclinical data demonstrating that EB-003 consistently exhibited a non-hallucinogenic profile in a highly sensitive GloSensor™ assay, complementing previously reported BRET assay findings
Announced promising results from preclinical in vitro experiments indicating no photoreactive potential for EB-003, further derisking its continued development as a potential treatment of neuropsychiatric disorders
